Cerus (CERS) Misses Q3 EPS by 4c
More News related to CERS
- Trading Review for Cerus Corp. Issued by Beacon Equity
- Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance for Proposed INTERCEPT Blood System Phase III Trial Design
- Cerus (CERS) Halted As FDA To Review Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
- Cerus Corporation Stock Trading Halted; FDA Blood Products Advisory Committee to Review and Discuss Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
- Cerus (CERS) Misses Q3 EPS by 4c
More News related to Earnings
- Keefe, Bruyette & Woods Downgrades First State Bancorporation (FSNM) to Market Perform
- Keefe, Bruyette & Woods Downgrades R&G Financial (RGFC) to Market Perform
Cerus (NASDAQ: CERS) reports a Q3 loss of $0.16, 4 cents worse than the analyst estimate of ($0.12). Revenue for the quarter was $4.8 million, which compares to the estimate of $5.53 million.
Related Categories
EarningsStocks Mentioned
-0.05Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Ceres
Richard Seff on Oct 30, 2009 10:57 AMIt seems to me Ceres is very responsibly handling its money management, and I would predict far more salubrious reports in the coming quarters.